心脏衰竭患者的结构性心脏干预:JACC科学声明
Rebecca T Hahn1, JoAnn Lindenfeld2, Scott D Lim3
1Division of Cardiology, Columbia University Medical Center, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA.
Journal of the American College of Cardiology
|August 21, 2024
概括
过导管干预为心力衰竭患者提供了新的希望,这些患者有诸如心室重塑和门疾病等结构问题,特别是当手术不是一种选择时. 这些皮肤穿透的策略为持续的症状提供了替代方案,尽管医疗治疗.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 干预心脏病学 干预心脏病学
背景情况:
- 病态左心室重塑和膜心脏病是心力衰竭表现和结果的关键因素.
- 这些情况可能会限制心力衰竭的标准指南导向医学治疗的疗效.
- 手术干预是已知的治疗方法,但可能不适合所有患者.
研究的目的:
- 审查当前和试验性皮肤穿透策略,以管理导致心力衰竭的结构性心脏病.
- 专注于扩大左心室心肌病和膜心脏病作为特定的结构性贡献者.
- 提供关于跨导管干预作用的科学陈述.
主要方法:
- 审查当前可用的穿皮治疗策略.
- 审查正在研究的皮肤穿策略.
- 专注于针对特定结构性心脏病的跨导管干预.
主要成果:
- 越来越多的证据支持通过导管干预作为心力衰竭的可行选择.
- 这些选择特别适用于患有持续症状的患者,尽管他们接受了最佳的医学治疗.
- 透导管方法解决了在特定患者群体中手术选择的局限性.
结论:
- 透导管干预措施在管理导致心力衰竭的结构性心脏病方面取得了重大进展.
- 穿皮策略为患有扩张左心室心肌病和膜心脏病的患者提供了替代的治疗途径.
- 该审查强调了心力衰竭治疗的不断变化的景观,超出了传统的手术方法.
相关概念视频
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352


